Atlas Trials

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Clinical trial NCT01056276 · COMPLETED

Trial details

NCT number
NCT01056276
Sponsor
SCRI Development Innovations, LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2010-05-01
Primary completion
2015-08-01
Enrollment
59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.